JASCHINSKI, FRANK,JANICOT, MICHEL,UHLMANN, EUGEN,LEO, EUGEN
申请号：
CA2908101
公开号：
CA2908101A1
申请日:
2014.03.27
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
The invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the TGF-beta1, TGF-beta2 or TGF-beta3 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2'-fluoro, 2'-O- methoxy and/or 2'-O-methyl modified nucleotides. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in a method for the prevention and/or treatment of glaucoma, posterior capsular opacification, dry eye, Marfan or Loeys- Dietz syndrome, riboblastoma, choroidcarcinoma, macular degeneration, such as age- related macular degeneration, diabetic macular endma, or cataract.
